Novo Nordisk (NVO 0.64%) is in the spotlight after cutting guidance again, but analysts remain optimistic. With Ozempic and Wegovy driving strong sales and a 52% upside potential, this could be one of the best comeback stories in pharma.
Stock prices used were the market prices of Nov. 10, 2025. The video was published on Nov. 12, 2025.
